PHST Pharsight Corp (MM)

Dr. Helen Kastrissios Will Present on Communicating the Value of Pharmacodynamic Modeling in Clinical Drug Development MOUNTAIN VIEW, Calif., May 27 /PRNewswire-FirstCall/ -- Pharsight Corporation (NASDAQ:PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Helen Kastrissios, Ph.D., senior scientist, Pharsight Strategic Consulting Services, has been invited to present to clinical and regulatory professionals attending the Association of Regulatory and Clinical Scientists (ARCS) 17th Annual Congress. The Congress will be held at the Sydney Convention and Exhibition Centre in Sydney, Australia from May 28-30, 2008. Dr. Kastrissios will present on May 30, joining other leading experts from the pharmaceutical industry and academia in a session on clinical applications of pharmacodynamic modeling in drug development. Dr. Kastrissios' presentation, entitled "Communicating the Value of Pharmacodynamic Modeling in Drug Development," will include several case studies describing how predictive drug-disease models have been used to support dose selection, compare the product profile of a new drug versus marketed competitors utilizing public-source literature data, and communicate model-based results to clinical project teams to support program decision- making. Presentation slides from Dr. Kastrissios' talk will be available at http://www.pharsight.com/ following the ARCS Congress. "Model-based drug development has significant value for optimizing drug therapy and for improving the confidence of drug development decisions," said Shawn O'Connor, president, CEO, and chairman of Pharsight. "Drug development teams can benefit from the quantitative application of drug-disease models to simulate expected clinical responses of new compounds, to support critical program strategies and enhance study design decisions. Pharsight is pleased to participate at the ARCS Congress, where we look forward to sharing our perspective with industry colleagues on the strategic use of modeling and simulation to improve drug development knowledge, productivity and decision- making." Further information on the ARCS Congress can be found at http://www.arcs.com.au/. About Pharsight Corporation Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products. Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com/. Registered Trademarks and Trademarks Pharsight is a registered trademark of Pharsight Corporation. All other brand or product names mentioned in this documentation are trademarks or registered trademarks of their respective companies or organizations. DATASOURCE: Pharsight Corporation CONTACT: Investors, Douglas Sherk, or Matthew Selinger, +1-415-896-6820, or Media, Steve DiMattia, or Donald Takaya, +1-646-201-5445, all of EVC Group for Pharsight Corporation Web site: http://www.pharsight.com/ http://www.arcs.com.au/

Copyright